Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 78
Semaglutide and the cost of CV benefit
A 2026 cost-effectiveness review places semaglutide, a GLP-1 agonist, in the moderate tier for preventing cardiovascular events. Here is what that means.
Semaglutide and heart risk: a 2026 review
A 2026 meta-analysis of 11 trials found semaglutide cut major cardiovascular events by about a third, similarly in people with and without diabetes.
Semaglutide for non-diabetic CKD: review
A 2026 review pooled 3 studies on semaglutide for non-diabetic obesity with kidney disease or hypertension. The signal is early, not long-term.
Semaglutide and the silent HFpEF signal
A 2026 meta-analysis of six trials links semaglutide to lower NT-proBNP, better symptom scores and fewer heart-failure hospitalisations in obesity-driven HFpEF.
How semaglutide works across the body
A 2026 review reads semaglutide through a systems medicine lens, tracing the GLP-1 receptor agonist from trial outcomes to the molecular mediators underneath.
Weight-loss drugs and hypertension
A Cochrane review of eight trials finds insufficient evidence that weight-loss drugs cut mortality or cardiovascular events in hypertensive patients.
Eating disorder screens predict GLP-1 use
A US survey of 1,309 adults links positive eating disorder screens to higher GLP-1 awareness and telehealth drug-seeking.
GLP-1 drugs improve ratio but cut muscle
A 2026 meta-analysis of 7 RCTs finds GLP-1 receptor agonists raise the lean-to-fat ratio while causing a 1.74 kg average absolute lean mass loss.
GLP-1 drugs and lung safety: what we know
A 2026 systematic review examines pulmonary adverse events with GLP-1 receptor agonists, from mild upper-airway infections to perioperative aspiration risk.
Semaglutide tied to lower seizure risk
A target trial emulation using the All of Us database found semaglutide users had roughly half the seizure risk of adults on other glucose-lowering drugs.
Semaglutide may protect joints via muscle
A 2026 mouse study reports that semaglutide restores muscle mitochondrial function, raises glutamine, and reduces cartilage inflammation.
Semaglutide CV edge over tirzepatide
A 47-trial meta-analysis finds semaglutide cuts MACE by 29% and CV death by 19%. Tirzepatide trends protective but lacks the trial base to confirm it.